Latest news for Harvia (OTC:HRVFF) Stock

Harvia PLC is a sauna and spa company. The company's brands and product range are well known in the market and the company's comprehensive product range aims to meet the needs of the international sauna and spa market, both for professionals and consumers. The group employs more than 800 professionals in Finland, China and Hong Kong, Romania, Austria, the United States, Germany, Estonia and Russia. The company's largest production plant for saunas and sauna components is also located in Muurame in connection with Harvia's head office.

Harvia PLC

The Board of Directors (Board) of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.allegion.com%2Fcorp%2Fen%2Findex.html&amp;esheet=54121951&amp;newsitemid=20240916880948&amp;lan=en-US&amp;anchor=Allegion+plc&amp;index=1&amp;md5=5c71b815672e2f6ec8d90e0bf2ef9444">Allegion plc</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>), a leading global security products and solutions provider, has elected <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.allegion.com%2Fcorp%2Fen%2Fabout%2Fleadership%2FLauren-Peters.html&amp;esheet=54121951&amp;newsitemid=20240916880948&amp;lan=en-US&amp;anchor=Lauren+B.+Peters&amp;index=2&amp;md5=bae59c1d10bed435b2631ce159fe625d">Lauren B. Peters</a> as its next chair, effective Sept. 11, 2024. Peters has served as a member of Allegion's Board since 2021 and will succeed <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.allegion.com%2Fcorp%2Fen%2Fabout%2Fleadership%2Fkirk-hachigian.html&amp;esheet=54121951&amp;newsitemid=20240916880948&amp;lan=en-US&amp;anchor=Kirk+S.+Hachigian&amp;index=3&amp;md5=87720626702dda6c09caf44879c4bcfc">Kirk S. Hachigian</a>, who is retiring from the Board at the end of his term in June 2025.
Peters is former executive vice president and chief financial officer of Foot Locker, Inc., where she built a track record of expanding profits and implementing innovative solutions while also leading major acquisitions, integrations and strategic investments. With deep expertise in positioning global, publicly held companies for growth, Peters currently serves as a board member for La-Z-Boy and Victoria's Secret, in addition to Allegion.

News

Management

ALLE

Allegion Board of Directors Elects Lauren B. Peters As Chair, Effective September 11, 2024

B of A Securities analyst Derik De Bruin maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and raises the price target from $600 to $675.

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $675

Project Rosa Boosts Soluna's Capacity with 187 MW of Sustainable Energy for AI and Bitcoin Mining
Soluna Holdings, Inc. ("SHI" or the "Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>), a developer of green data centers for intensive computing applications including Bitcoin mining and AI, announced today that it has signed term sheets for power and land for Project Rosa, a new 187 MW Data Center indicating an important step forward in the Company's expansion efforts.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20240916477316/en/">https://www.businesswire.com/news/home/20240916477316/en/</a>
Project Rosa will be strategically co-located with a 240 MW wind farm in Texas, enabling the project to directly harness a substantial share of renewable energy. Soluna has secured 60 acres of land for this project's development, an important milestone in its journey to shovel readiness.

SLNH

Soluna Signs Term Sheet with Renewable Energy Leader For New Data Center Project

<ul>
<li>Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024</li>
<li>In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% ORR (34.5% ORR including partial response after data cut-off) versus 18.5% ORR for KEYTRUDA</li>
<li>Efti in combination with KEYTRUDA led to a high durability of response of 17.5 months in patients with any PD-L1 expression and combination continues to have favourable safety profile</li>
<li>Statistically significant increase in absolute lymphocyte count biomarker seen in the efti in combination with KEYTRUDA arm shows efti's biological activity in a randomised setting
<ul>
<li>Based on the high unmet need and encouraging results to date, with Overall Survival expected in 2025, the path forward will be discussed with regulatory agencies</li>
</ul>
</li>
</ul>

Biotech

General

IMMP

Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer

Health Care

Sanofi Says Shipping BEYFORTUS 50mg And 100mg Injection Doses To Private Healthcare Providers And To The Centers For Disease Control And Prevention For Its Vaccines For Children

– Company remains committed to its mission to become a leader in developing differentiated product candidates targeting immune, inflammatory and fibrotic diseases
– Successful completion of nonclinical safety and toxicity studies and continued execution of regulatory requirements towards launch of Phase 1 human clinical study for lead program, PALI-2108 for the treatment of UC before year end &nbsp;
Carlsbad,&nbsp;CA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=rpFtMHlGFf46MiOPOfpVcfmtJHGNEnWhe8wnqtUcSXBoSMQr33upiNRVxL_jBGOr6GJ6sN1zI31xWiwQ-WF8x0Evdk6SbBGASUbwDCe0Bpg=">Palisade Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) ("Palisade," "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the launch of its new corporate branding and website, <a href="https://www.globenewswire.com/Tracker?data=c9xSk0PVpXM6oYUp2RcrdaL37PCCriJI029LshUtEcipofDLrTaqg0ZXu9MEhmjMLK__Gj1Gs-xqKREr1oWkWtK6qQPHyWH3STIuauqPr7g=">palisadebio.com</a> and reiterated its commitment to stakeholders by advancing its lead product candidate, PALI-2108.

PALI

Palisade Bio Launches New Corporate Branding And Reiterates Commitment To Advancing Next-Generation Precision Therapies, Remains Committed To Its Mission To Become A Leader In Developing Differentiated Product Candidates Targeting Immune, Inflammatory And Fibrotic Diseases

Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) will release earnings results for its fiscal 2025 first quarter, before the <a href="https://www.benzinga.com/quote/DRI/earnings">opening bell on Thursday, Sept. 19.</a>
Analysts expect the Orlando, Florida-based company to report quarterly earnings at $1.84 per share, up from $1.78 per share in the year-ago period. Darden Restaurants projects to report quarterly revenue of $2.8 billion for the quarter. according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
On July 17, Chuy's Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) and Darden Restaurants jointly announced that Darden will acquire Chuy's Holdings.
Darden Restaurants shares rose 1.1% to close at $160.25 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/DRI/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58b05502b85e93000174c0ed/andrew-charles">TD Cowen analyst Andrew Charles</a> reiterated a Hold rating with a price target of $150 on Sept. 12. This analyst has an accuracy rate of 69%.</li>
<li>Citigroup analyst Jon Tower maintained a Buy rating and cut the price target from $192 to $191 on Sept. 10. This analyst has an accuracy rate of 73%.</li>
<li><a href="https://www.benzinga.com/topic/nick-setyan">Wedbush analyst Nick Setyan</a> reiterated an Outperform rating with a price target of $170 on Sept. 10. This analyst has an accuracy rate of 69%.</li>
<li>Raymond James analyst Brian Vaccaro maintained an Outperform rating with a price target of $160 on Aug. 20. This analyst has an accuracy rate of 81%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5df37c17bffdfc0001d738fc/brian-mullan">Piper Sandler analyst Brian Mullan </a>maintained a Neutral rating and cut the price target from $163 to $159 on July 22. This analyst has an accuracy rate of 78%.</li>
</ul>
Considering buying DRI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="523" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16031940/image-112-1024x523.png" alt="" class="wp-image-548912" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16031940/image-112-1024x523.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16031940/image-112-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16031940/image-112-768x392.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16031940/image-112.png 1316w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

Earnings

Markets

Trading Ideas

CHUY

Darden Restaurants Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ftxtav.com%2F&amp;esheet=54122188&amp;newsitemid=20240916045313&amp;lan=en-US&amp;anchor=Textron+Aviation+Inc.&amp;index=1&amp;md5=4cffb995e32a063799a849a1e54334b5">Textron Aviation Inc.</a>, a <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.textron.com%2F&amp;esheet=54122188&amp;newsitemid=20240916045313&amp;lan=en-US&amp;anchor=Textron+Inc.&amp;index=2&amp;md5=4645e1d0dab54d1dac8cc1c2fe5f69f6">Textron Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) company, today announced that the company has received Federal Aviation Administration (FAA) approval of the company's new Safety Management System (SMS) implementation plan to support the design and manufacturing of Cessna and Beechcraft aircraft. This approval builds on the company's previously FAA-accepted and approved SMS program supporting the maintenance and support of iconic Cessna and Beechcraft aircraft, and underscores the company's dedication to maintaining the highest standards of product quality at every level of operations.

Textron Aviation Earns FAA Approval For Safety Management System In Aircraft Design And Manufacturing

B of A Securities analyst Tazeen Ahmad maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and raises the price target from $125 to $150.

BNTX

B of A Securities Maintains Buy on BioNTech, Raises Price Target to $150

Program expands global reach with mentorship, partnership and funding opportunities for disruptive startups in the U.S. and EMEA; NVIDIA supports second annual CrowdStrike Accelerator
Fal.Con 2024--<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fen-us%2F&amp;esheet=54122204&amp;newsitemid=20240916470788&amp;lan=en-US&amp;anchor=CrowdStrike&amp;index=1&amp;md5=7b7915109e90775a1f85047d80b85e01">CrowdStrike</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) today announced the launch of its second annual Cybersecurity Startup Accelerator with Amazon Web Services (AWS). NVIDIA also joins in supporting the Accelerator program, powering the next generation of artificial intelligence (AI) and cloud security startups. Targeting cybersecurity's next market-defining disruptors across the U.S. and EMEA, AWS and CrowdStrike with NVIDIA through its Inception program, will provide mentorship, technical expertise, funding and go-to-market opportunities.
Applications for the AWS and CrowdStrike Cybersecurity Startup Accelerator with NVIDIA are open from September 16, 2024 to January 10, 2025. Selected startups will be enrolled in a free eight-week program developed by AWS, CrowdStrike and NVIDIA that offers mentorship and guidance from industry experts and executives. Startups will also have access to top-tier global cybersecurity investors, enablement sessions, and up to $25,000 in AWS Activate credits, among other exclusive benefits.

AMZN

CRWD

NVDA

CrowdStrike Expands Cybersecurity Startup Accelerator With AWS And NVIDIA To Support The Next Generation Of Global Cloud Security Companies; NVIDIA Supports Second Annual CrowdStrike Accelerator

The Nasdaq 100 closed higher by around 0.5% during Friday's session. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Skyworks Solutions</h3>
<ul>
<li>The Trade: Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) SVP, Sales &amp; Marketing Carlos S Bori <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 9,321 shares</a> at an average price of $101.97. The insider received around $950,462 from selling those shares.</li>
<li>What's Happening: On July 30, Skyworks Solutions reported quarterly earnings of $1.21 per share which missed the analyst consensus estimate of $1.23 and is a 30.06% decrease from the same period last year.</li>
<li>What Skyworks Solutions Does: Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. </li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091624&amp;t=be2bearmibe3na1"> latest SWKS new</a>s. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16053917/image-113.png" alt="" class="wp-image-549152" style="width:736px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16053917/image-113.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16053917/image-113-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16053917/image-113-768x717.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Dell Technologies</h3>
<ul>
<li>The Trade: Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) CEO Michael S Dell <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 3,920,259 shares</a> at an average price of $110.62. The insider received around $433.7 million from selling those shares.</li>
<li>What's Happening: On Sept. 10, Susquehanna analyst Mehdi Hosseini initiated coverage on Dell with a Neutral rating and announced a price target of $120.</li>
<li>What Dell Technologies Does: Dell Technologies is a broad information technology vendor, primarily supplying hardware to enterprises. </li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091624&amp;t=be2bearmibe3na1">trend in DELL stock. </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16053931/image-114.png" alt="" class="wp-image-549153" style="width:712px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16053931/image-114.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16053931/image-114-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16053931/image-114-768x709.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">Warner Music Group</h3>
<ul>
<li>The Trade: Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) CEO Max Lousada <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 250,769 shares</a> at an average price of $28.09. The insider received around $7.04 million from selling those shares.</li>
<li>What's Happening: On Sept. 12, Tigress Financial analyst Ivan Feinseth maintained Warner Music with a Buy and lowered the price target from $52 to $44.</li>
<li>What Warner Music Group Does: Warner Music is the third-largest of the three major record companies. </li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091624&amp;t=be2bearmibe3na1"> breakout in WMG shares.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="883" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16054007/image-115.png" alt="" class="wp-image-549154" style="width:697px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16054007/image-115.png 883w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16054007/image-115-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16054007/image-115-768x723.png 768w" sizes="(max-width: 883px) 100vw, 883px" /></a></figure>
<h3 class="wp-block-heading">Netflix</h3>
<ul>
<li>The Trade: Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) Director Jay C Hoag <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 43,750 share</a>sat an average price of $687.08. The insider received around $30.06 million from selling those shares.</li>
<li>What's Happening: Netflix will post its third quarter 2024 financial results on Thursday, Oct. 17.</li>
<li>What Netflix Does: Netflix&#8217;s relatively simple business model involves only one business, its streaming service. </li>
<li>Benzinga Pro's earnings calendar was used to track upcoming <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091624&amp;t=be2bearmibe3na1">NFLX&#8217;s earnings report</a>s. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="892" height="802" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16054051/image-1-31.png" alt="" class="wp-image-549157" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16054051/image-1-31.png 892w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16054051/image-1-31-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/16054051/image-1-31-768x691.png 768w" sizes="(max-width: 892px) 100vw, 892px" /></a></figure>
Check This Out:<a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

Short Ideas

Pre-Market Outlook

DELL

NFLX

SWKS

Netflix, Dell And 2 Other Stocks Executives Are Selling

WIIM

APVO

Aptevo Therapeutics shares are trading higher after the company and Alligator Bioscience announced interim data from the Phase 1 trial of ALG.APV-527 monotherapy, showing 60% of evaluable patients achieved stable disease in a solid tumor study.

Aptevo Therapeutics And Alligator Bioscience Announce Interim Data From Phase 1 Trial Of ALG.APV-527 Monotherapy; 60% Of Evaluable Patients Achieved Stable Disease In Solid Tumor Study

Partnership leverages Korro's proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; initially for cardiometabolic diseases &nbsp;
Total deal value of up to $530 million in upfront, development, and commercial milestone payments, in addition to tiered royalties and R&amp;D funding
CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>), a biopharmaceutical company focused on developing a potential new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases, today announced a collaboration with Novo Nordisk, a global healthcare company, to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases. The collaboration brings together Novo Nordisk's deep cardiometabolic disease understanding and drug development experience with Korro's proprietary platform to develop RNA editing product candidates for two undisclosed targets.

KRRO

Korro Bio Announces Collaboration With Novo Nordisk To Develop Two Therapeutic Candidates, Leveraging Korro's Proprietary OPERA Platform To Enable Its Oligonucleotide-Directed RNA Edits Into Two Undisclosed Targets; Initially For Cardiometabolic Diseases; Total Deal Value Of Up To $530M In Upfront, Development, And Commercial Milestone Payments, In Addition To Tiered Royalties And R&D Funding

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer discretionary sector.
<h3 class="wp-block-heading">Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>)</h3>
<ul>
<li>Dividend Yield: 10.14%</li>
<li>JP Morgan analyst Matthew Boss downgraded the stock from Neutral to Underweight with a price target of $19 on Aug. 29. This analyst has an accuracy rate of 67%.</li>
<li>Evercore ISI Group analyst Michael Binetti maintained an In-Line rating and decreased the price target from $22 to $20 on Aug. 29. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Aug. 28, Kohl&#8217;s posted better-than-expected second-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted <a href="https://pro.benzinga.com/dashboard">to latest KSS news</a></li>
</ul>
<h3 class="wp-block-heading">Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>)</h3>
Dividend Yield: 7.10%
<ul>
<li>B of A Securities analyst Rafe Jadrosich reinstated an Underperform rating with a price target of $88 on July 30. This analyst has an accuracy rate of 73%</li>
<li>RBC Capital analyst Mike Dahl maintained an Underperform rating and cut the price target from $79 to $76 on July 26. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Aug. 19, Whirlpool declared a quarterly dividend of $1.75 per share on the Company&#8217;s common stock.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://pro.benzinga.com/dashboard"> trend in WHR stock.</a></li>
</ul>
<h3 class="wp-block-heading">Bloomin&#8217; Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>)</h3>
<ul>
<li>Dividend Yield: 5.73%</li>
<li>Citigroup analyst Jon Tower maintained a Neutral rating and cut the price target from $22 to $20 on Aug. 19. This analyst has an accuracy rate of 73%.</li>
<li>Deutsche Bank analyst Lauren Silberman maintained a Hold rating and slashed the price target from $26 to $19 on Aug. 7. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: On Aug. 26, Bloomin&#8217; Brands named Michael L. Spanos as Chief Executive Officer.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential b<a href="https://pro.benzinga.com/dashboard">reakout in BLMN shares.</a></li>
</ul>

<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

Dividends

BLMN

Wall Street's Most Accurate Analysts Spotlight On 3 Consumer Stocks With Over 5% Dividend Yield

CACI

CACI To Purchase Azure Summit Technology For $1.275B In Cash; Expects To Close In Second Quarter Of FY25

Glauber Contessoto, popularly known as the &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38297055/dogecoin-millionaire-consoles-trader-who-lost-1m-on-pepe-long-i-lost-3m-before-bro-and-im-">Dogecoin millionaire</a>,&#8221; shared his predictions for a 2025 meme coin bull run, highlighting two key narratives.
What Happened: Contessoto <a href="https://x.com/ProTheDoge/status/1835502907447513564">predicted</a> that Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) on the Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) blockchain and Brett (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BRETT</a>) on Base would become the most popular meme coins. He also foresees significant activity around Boys Club Members Andy (CRYPTO: ANDY).
Contessoto further stated, "As it stands right now we can all agree PEPE on ETH with the highest current market capitalization ($3 billion) is the clear WINNER of all Pepe coins created." 
He believes Pepe and Brett could follow the trajectory of Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) following Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) in interest and liquidity and eventually flipping it in valuation.
Contessoto predicted a resurgence of the "Dogeverse", led by DOGE, with a significant run up for SHIB and Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>). He believes that Neiro (CRYPTO: NEIRO) on ETH will lead the pack in this universe: "I honestly think the strong communities behind DOGE and SHIB will find common ground getting behind NEIRO as she is the younger sister of DOGE and the next successor in the DOGE family to carry the torch."
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40855248/pepe-down-50-from-its-all-time-high-but-time-to-be-bearish-was-at-the-highs-trader-caution">Pepe Down 50% From Its All-Time High But: &#8216;Time To Be Bearish Was At The Highs,&#8217; Trader Cautions</a>
Why It Matters: Contessoto stated that there could be other meme coins that spike in 2025, which are not connected to these two main universes. But these two are the "biggest narratives to understand going into next year."
He <a href="https://x.com/ProTheDoge/status/1835419217253826875">noted</a> that with many <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40829667/dogecoin-up-4-7-benefits-from-another-doge-tweet-by-elon-musk">Elon meta</a> and Doge-related meme coins recently launched, there could be a lot of DOGE pop-ups on crypto traders' timelines in the coming months.
Meanwhile, Contessoto expressed in another <a href="https://x.com/ProTheDoge/status/1835567508096692398">tweet</a> that he wishes to collect the entire Pepeverse while he already has Pepe, Brett, Andy, and Wolf, the prediction is Pepe to first hit $10 billion valuation and Brett to follow with a $5 billion.
What&#8217;s Next: The influence of meme coins is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40736466/meme-coins-are-in-an-unregulated-untouchable-position-trader-notes-main-reason-for-massive">Meme Coins Are In An &#8216;Unregulated Untouchable Position,&#8217; Trader Notes Main Reason For &#8216;Massive Trading&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BRETT

$DOGE

$ETH

$FLOKI

$PEPE

$SHIB

'Dogecoin Millionaire' Highlights Pepe and Dogecoin As 'Two Biggest Meme Narratives For 2025,' Shiba Inu, Floki To Follow

<a href="https://www.globenewswire.com/Tracker?data=N8oH61z7x2Dk2IYP_NwGt-VKHDzJ7tlcBJw3vGc-tzotNJvzrSN2ki_M0wizdzVxqvuF-HUnFL7aZj0vsEXJXqGJEGqtUln-vbV__NGGkaw=">Apollomics Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today a poster presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024 in Barcelona, Spain.

APLM

Apollomics Presents Vebreltinib Data In Patients With Non-Small Cell Lung Cancer With METex14 Skipping Mutations At ESMO Congress 2024

Yoshitsu Co., Ltd ("Yoshitsu" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, as well as other products in&nbsp;Hong Kong,&nbsp;Japan,&nbsp;North America, and the&nbsp;United Kingdom, today announced the official opening of two new franchise stores (the "Stores") under its "Reiwatakiya" brand in Hong Kong in September 2024. This expansion is expected to further enhance the Company's market presence and boost brand recognition in the region.

TKLF

Yoshitsu Co. Expands Reiwatakiya Brand In Hong Kong, Plans Broader Expansion Across Asia

The U.S. State Department has categorically denied accusations of CIA involvement in an alleged plot to assassinate Venezuelan President Nicolás Maduro. This follows the arrest of six foreigners, including a U.S. Navy SEAL, by Venezuelan authorities.
What Happened: The State Department dismissed the allegations as &#8220;categorically false&#8221;. The U.S. continues to push for a democratic resolution to Venezuela&#8217;s ongoing political crisis, CNN <a href="https://edition.cnn.com/2024/09/14/americas/venezuela-arrests-americans-seizes-rifles-intl-latam/index.html">reported</a> on Monday.
Venezuela had previously announced the arrest of six individuals, accusing them of involvement in a plot to destabilize the country, which has been in political chaos since disputed elections earlier this year. Venezuelan Interior Minister Diosdado Cabello claimed that the alleged plot was a CIA scheme aimed at assassinating Maduro.
See Also: <a href="https://www.benzinga.com/news/24/09/40869772/scaramucci-says-trump-loomer-union-marks-dangerous-shift-towards-extreme-nativism?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Scaramucci Says Trump-Loomer Union Marks Dangerous Shift Towards Extreme Nativism</a>
The arrests occurred amidst a refusal by Venezuela&#8217;s opposition, several Latin American leaders, and the United States to recognize Maduro&#8217;s contested election victory, leading to deadly protests and thousands of arrests.
Why It Matters: The U.S. has been actively involved in Venezuelan politics, with efforts to resolve the political crisis. In August, the U.S. reportedly offered <a href="https://www.benzinga.com/news/24/08/40307039/us-proposes-amnesty-for-venezuelas-nicolas-maduro-for-stepping-down">amnesty to Maduro</a> if he stepped down from his position. This was part of a broader effort to persuade Maduro to leave office before his term ends in January.
Following the contested reelection of Maduro in July, the U.S. was reportedly preparing to impose <a href="https://www.benzinga.com/news/24/09/40684235/us-set-to-impose-fresh-sanctions-on-venezuelan-officials-involved-in-nicol-s-maduros-reelection-repo">new sanctions</a> on Venezuelan government officials. The proposed sanctions targeted key figures who allegedly collaborated with Maduro to manipulate the July 28 vote.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40868156/former-democratic-senator-al-franken-says-biden-is-wrong-to-impose-higher-tariffs-on-evs-made-in-chi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Former Democratic Senator Al Franken Says Biden Is Wrong To Impose Higher Tariffs On EVs Made In China</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Harvia

News

Latest news for Harvia (OTC:HRVFF) Stock